ESP 01Alternative Names: Breast cancer therapeutic - Espera Pharma; ESP-01
Latest Information Update: 20 May 2015
At a glance
- Originator Eli Lilly
- Developer Eli Lilly; Esperas Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell division inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours